Allurion Technologies Inc. (NYSE:ALUR – Free Report) – Equities researchers at Chardan Capital boosted their FY2024 earnings per share (EPS) estimates for shares of Allurion Technologies in a report issued on Sunday, January 12th. Chardan Capital analyst K. Nakae now expects that the company will post earnings per share of ($7.63) for the year, up from their previous forecast of ($7.75). Chardan Capital has a “Neutral” rating on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($0.41) per share. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.82) EPS.
Separately, TD Cowen assumed coverage on shares of Allurion Technologies in a research note on Wednesday, October 2nd. They issued a “buy” rating and a $50.00 price target on the stock. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $71.88.
Allurion Technologies Price Performance
Shares of ALUR opened at $3.13 on Wednesday. The company’s 50-day moving average is $9.96 and its 200-day moving average is $15.87. Allurion Technologies has a fifty-two week low of $2.72 and a fifty-two week high of $98.75.
Institutional Investors Weigh In On Allurion Technologies
A hedge fund recently bought a new stake in Allurion Technologies stock. CVI Holdings LLC acquired a new position in Allurion Technologies Inc. (NYSE:ALUR – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 521,440 shares of the company’s stock, valued at approximately $520,000. Allurion Technologies makes up approximately 0.5% of CVI Holdings LLC’s investment portfolio, making the stock its 28th biggest position. CVI Holdings LLC owned 1.09% of Allurion Technologies at the end of the most recent reporting period. 21.39% of the stock is currently owned by hedge funds and other institutional investors.
Allurion Technologies Company Profile
Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Further Reading
- Five stocks we like better than Allurion Technologies
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Read Stock Charts for Beginners
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
